Obama Faces Widespread Public Distrust on Iran Deal
President Obama will try to drum up support for the U.S.-Iran nuclear deal Wednesday afternoon at a news conference. But with widespread public disdain and distrust of Iran, Obama may have trouble convincing Americans of the wisdom of dealing with a long-time arch enemy in the Middle East.
The U.S. and Iran on Tuesday announced an agreement that would potentially block Iran’s development of a nuclear weapon for at least a decade while lifting international economic sanctions against Tehran. However, a new AP-GfK poll that was conducted just ahead of the announcement found that Americans only narrowly back diplomatic relations with the hardline Islamic government, and many want to see the sanctions kept in place.
Related: The 8 Most Important Things to Know About the Iran Nuclear Deal
Just 51 percent of those interviewed said the U.S. should have diplomatic relations with Iran while 45 percent said it shouldn’t. At the same time, 77 percent of those interviewed said the harsh U.S. and international economic sanctions against Iran should be preserved at current levels or even increased.
Only 12 percent of those interviewed thought sanctions should be decreased and seven percent said they should be eliminated altogether.
The public’s wariness and distrust of dating back to the 1979 Iranian revolution and U.S. hostage crisis matches the reception the nuclear agreement has received on Capitol Hill where most Republicans and some Democrats say they fear Obama has conceded too much to a country that has fomented terrorist activities throughout the Middle East and has repeatedly vowed to destroy Israel.
Fifty-six percent of Americans consider Iran to be an enemy, according to the poll conducted last Thursday through Monday, while an additional 31 percent consider Iran to be unfriendly but not an enemy. More than 70 percent of Republicans, half of all independents and 45 percent of Democrats described Iran as the enemy.
Related: Clinton Cautious in Her Praise of a Nuclear Deal She Helped to Orchestrate
Before the agreement was announced, six in ten Americans said they disapproved of Obama's handling of the U.S. relationship with Iran, while just over a third approved.
Obama is likely to prevail in pushing the nuclear non-proliferation agreement through Congress over the next two months, despite near-unanimous opposition from Senate Majority Leader Mitch McConnell, House Speaker John Boehner and other leaders and rank and file Republicans. Still, he will need to hold in place at least 34 of the 46 Democrats in the Senate to create a veto-proof firewall in the event Republicans push through a resolution of disapproval of the nuclear deal.
That means that Obama cannot afford any more than 12 Democratic defections to keep the agreement alive. Yesterday, Obama and Vice President Joe Biden began working the phones to shore up support on Capitol Hill, and the president will continue that effort during this afternoon’s White House press conference.
During an interview yesterday with Tom Friedman of The New York Times, Obama stressed that the deal prevented a pathway for Iran to develop a nuclear weapon while making it clear he shared Americans’ distrust of the Iranian government and had limited expectations of improved relations down the road.
Related: Iran Agrees to Limit Nuclear Weapon in Historic Deal
When announcing the deal yesterday, Obama said, “This deal is not built on trust -- it's built on verification…. We will, for the first time, be in a position to verify that Iran is meeting all of these commitments. International nuclear inspectors will have access to Iran's nuclear program -- where necessary, when necessary. This is the most comprehensive and intrusive verification regime that we have ever negotiated. If Iran tries to divert raw materials to covert facilities, inspectors will be able to access any suspicious locations.”
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.